Addyi, the female libido drug developed by Sprout Pharmaceuticals, was rejected twice by the FDA and abandoned by Boehringer Ingelheim before a public lobbying campaign helped push it onto the market last month. Valeant dropped $1 billion to buy Sprout soon after the drug's FDA approval. That bet isn't working out as planned, at least so far.
Boehringer Ingelheim, maker of idiopathic pulmonary fibrosis drug Ofev, has been a sponsor of the Pulmonary Fibrosis Foundation since 2011. But now, it's beefing up its support for the organization to raise awareness of the disease.
German drugmaker Boehringer Ingelheim is planning to dial down its R&D spend over the next 5 years, turning to a growing stable of external collaborators to feed its pipeline of new therapeutics.
Boehringer Ingelheim has picked a member of the founding family as CEO for the first time in a quarter of a century to help it through its lean times. The drugmaker announced today that Hubertus von Baumbach, a great-grandson of founder Albert Boehringer, would take over when its current leader, Andreas Barner, steps out of that role next year.
For the first time since 2013, Bristol-Myers Squibb reported a year-over-year quarterly ad spending increase. Advertising and product promotion costs rose 13% to $193 million, following two quarters of double-digit decreases this year--and a 14% overall decrease for all of 2014. The last time ad spending was up year over year was 2013's fourth quarter.
Boehringer Ingelheim has expanded its crowdsourced R&D program into the field of psychiatric diseases, broadening its partnership with Germany's BioMed X to spotlight new therapies.
Within weeks, Boehringer Ingelheim's U.S. generics operation, Roxane, will become part of Hikma, which picked it up in July in a $2.7 billion deal. But for now, it is the responsibility of the German company and so is the recall that the Ohio operation is undertaking.
The lack of an antidote to reverse the effects of new-age anticoagulants has kept some doctors from prescribing them. But now, Boehringer Ingelheim is hoping that'll change.
Boehringer Ingelheim picked up an FDA nod for an injection designed to reverse the effects of its blockbuster anticoagulant Pradaxa, marking the first approval for an antidote to a next-generation blood thinner.
Boehringer Ingelheim's next-gen anticoagulant, Pradaxa, has been plagued by safety worries that have cropped up since its 2010 FDA approval. And according to one watchdog group, that's because the agency was "lax" and "permissive" in reviewing the drug in the first place.